Skip to main content

Table 2 Efficacy evaluations at the end-of-treatment visit in ITT population (N = 89)

From: Multicenter, randomized, double-blind clinical trial to evaluate efficacy and safety of combined glucosamine sulfate and chondroitin sulfate capsules for treating knee osteoarthritis

  Glucosamine sulfate and chondroitin sulfate (N = 45) Cosamin DS® (N = 44) p value
Analgesic efficacy as evaluated by the Investigator, N (%)
 Efficient 40 (88.9) 38 (86.4) 0.717
 Inefficient 5 (11.1) 6 (13.6)  
Overall efficacy as evaluated by the Investigator, N (%)
 Efficient 34 (75.6) 35 (79.5) 0.652
 Inefficient 11 (24.4) 9 (20.5)  
Reduced pain intensity as evaluated by the subject, VAS (0 to 10 cm), average ± SDa 4.27 ± 2.83 3.58 ± 2.56 0.230
Efficacy as evaluated by the investigator (based on subjects pain VAS), N (%)
 Excellent 16 (35.6) 11 (25.0) 0.358
 Very good 10 (22.3) 12 (27.3) 0.630
 Good 6 (13.3) 6 (13.6) >  0.999
 Average 8 (17.8) 9 (20.5) 0.793
 Poor 5 (11.1) 6 (13.6) 0.758
Clinical efficacy as evaluated by the investigator, N (%)
 Excellent 8 (17.8) 8 (18.2) >  0.999
 Very good 15 (33.3) 16 (36.4) 0.826
 Good 11 (24.4) 11 (25.0) >  0.999
 Average 8 (17.8) 7 (15.9) >  0.999
 Poor 3 (6.7) 2 (4.5) >  0.999
  1. aWhen compared to visit 1. SD standard deviation, VAS visual analog scale, ITT intention to treat